Relvar Ellipta is a once-daily dual combination treatment comprising fluticasone furoate, an inhaled corticosteroid and vilanterol, a long-acting beta2-agonist, in a single inhaler, the Ellipta.

Relvar Ellipta is a once-daily dual combination treatment comprising fluticasone furoate, an inhaled corticosteroid and vilanterol, a long-acting beta2-agonist, in a single inhaler, the Ellipta.

Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in 2024 sales, followed by Relvar/Breo Ellipta and Seretide/Advair GlobalData is the patent company of ...